U.S. private equity firm Advent International and Singapore’s sovereign wealth fund on Friday said they are withdrawing their bid for Swedish drugmaker Orphan Biovitrum (Sobi), citing a low acceptance level.
Continue reading this premium story with a subscription to DealStreetAsia.
SubscribeAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
